TDV Placebo

BIOLOGICAL2 trials

Sponsors

Takeda

Conditions

Dengue FeverHealthy Volunteers

Phase 2

Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants

CompletedNCT02302066

TakedaDengue Fever

Start: 2014-12-05End: 2019-02-18Updated: 2020-02-24

Phase 3

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine

CompletedNCT03525119

TakedaHealthy Volunteers

Start: 2018-05-16End: 2019-07-09Updated: 2022-08-19

Related Papers

Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine

Expert Review of Vaccines2025-03-184 citations

Overcoming challenges of developing a live-attenuated dengue vaccine and the path forward

International Journal of Infectious Diseases2025-02-28

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country

Vaccine2023-01-1923 citations

Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting.

2022-01-2217 citations

Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine

The Journal of Infectious Diseases2021-01-2913 citations

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.

2020-03-1771 citations

Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.

2017-11-0662 citations

Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.

2017-03-3065 citations